New European Study Confirms Effectiveness of PSA Test Prostate Cancer Deaths Cut by Up to 31% and Unnecessary Biopsies by 33% New data from the European Randomized Study of Screening for Prostate Cancer (ERSPC) shows the PSA test reduces prostate cancer deaths by as much as 31 percent and unnecessary biopsies by as much as 33 percent. "This new ERSPC research provides scientifically-based data to show that taking the PSA test can save your life," said ZERO's CEO Skip Lockwood. "The PSA test is as important to men as a mammogram is to women. Everyone has the right to know if they have cancer."
The Life-Saving Benefits of PSA Screening The PSA test is today's best tool for early diagnosis and treatment of prostate cancer, and men should continue to be tested to protect their health.
Prostate Cancer Testing Is Best Option for Men Thanks to PSA testing, more than 90 percent of prostate cancers are caught before they spread to other areas of the body.
Amgen's Denosumab Reduces Bone Cancer Risk Amgen's Denosumab outpaced Novartis AG's Zometa in reducing the risk of serious bone complications among patients with advanced breast and prostate cancer, new study finds.
| 
No comments:
Post a Comment